Back

Clinical implications of atrial fibrillation recurrence vs. burden following catheter ablation: outcome data from 3 contemporary clinical trials using an insertable cardiac monitor

31 August 2024 (07:55 - 08:50)
Organised by: Logo
Congress Presentation Part of: New technologies and approaches in catheter ablation of atrial fibrillation Catheter Ablation of Arrhythmias ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Associate Professor Mehmet Kemal Aktas

University of Rochester, Rochester (United States of America)

7 More presentations in this session

Presentation thumbnail
HD grid versus circular mapping catheter for assessment of pulmonary vein (pv) reconnections
Doctor K. Manoharan (Brighton, GB)
Abstract Slides Video
Presentation thumbnail
Pulsed field ablation using additional mapping and substrate modification to treat atrial fibrillation - one year outcome comparison
Doctor M. Mergani (Clonmel, IE)
Abstract Slides Video
Presentation thumbnail
The prevalence and prognostic impact of low voltage zone in patients with cardiomyopathy after catheter ablation for atrial fibrillation
Doctor T. Oka (Suita, JP)
Abstract Slides Video
Presentation thumbnail
Comparative effectiveness of pulsed field ablation and cryoballoon ablation for atrial fibrillation: a systematic review and meta-analysis
Doctor M. Vilela (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Utilizing cluster analysis of biomarkers alongside echocardiographic deformation parameters to forecast the outcome of atrial fibrillation post-ablation
Professor Y. Li (Tainan, TW)
Abstract Slides Video

Access the full session

Session thumbnail
New technologies and approaches in catheter ablation of atrial fibrillation

The Event

Event poster

ESC Congress 2024

31 August 2024 07:55 CET
You may be interested in
thumbnail
Congress Presentation
Impact of pre-procedural atrial fibrillation burden on recurrences after ablation: findings from the ISOLATION cohort study
thumbnail
Congress Presentation
Why atrial fibrillation duration should be an endpoint in atrial fibrillation ablation trials
thumbnail
Congress Presentation
Real-world evaluation of atrial fibrillation burden and recurrence after ablation using ambulatory cardiac monitoring

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources